Ascendis Pharma A/S Sponsored ADR Forecast, price target & analysts
Ascendis Pharma A/S Sponsored ADR Target price 2025 - Analyst rating & recommendation
Ascendis Pharma A/S Sponsored ADR Classifications & Recommendation:
Ascendis Pharma A/S Sponsored ADR Price Target
| Target Price | $255.00 |
| Price | $199.22 |
| Potential |
28.00%
register free of charge
|
| Number of Estimates | 19 |
|
19 Analysts have issued a price target Ascendis Pharma A/S Sponsored ADR 2026 .
The average Ascendis Pharma A/S Sponsored ADR target price is $255.00.
This is
28.00%
register free of charge
$322.35
61.81%
register free of charge
$222.20
11.53%
register free of charge
|
|
| A rating was issued by 23 analysts: 22 Analysts recommend Ascendis Pharma A/S Sponsored ADR to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ascendis Pharma A/S Sponsored ADR stock has an average upside potential 2026 of
28.00%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 421.48 | 863.94 |
| 36.34% | 104.98% | |
| EBITDA Margin | -72.67% | -19.95% |
| 55.06% | 72.55% | |
| Net Margin | -103.97% | -19.70% |
| 42.40% | 81.05% |
17 Analysts have issued a sales forecast Ascendis Pharma A/S Sponsored ADR 2025 . The average Ascendis Pharma A/S Sponsored ADR sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Ascendis Pharma A/S Sponsored ADR EBITDA forecast 2025. The average Ascendis Pharma A/S Sponsored ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
17 Ascendis Pharma A/S Sponsored ADR Analysts have issued a net profit forecast 2025. The average Ascendis Pharma A/S Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -7.57 | -2.78 |
| 23.61% | 63.28% | |
| P/E | negative | |
| EV/Sales | 14.50 |
17 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast for earnings per share. The average Ascendis Pharma A/S Sponsored ADR EPS is
This results in the following potential growth metrics and future valuations:
Ascendis Pharma A/S Sponsored ADR...
Current Ascendis Pharma A/S Sponsored ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Raymond James |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Oct 13 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Oct 09 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Sep 02 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Raymond James:
Locked
➜
Locked
|
Oct 17 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Oct 13 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Oct 09 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Sep 02 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 19 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Aug 08 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
